Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16921176 | 0.94 | DNM1 (0.41) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL1362532 | 0.88 | LMNA (0.45) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL27883001 | 0.88 | DNM1 (0.40) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL25867174 | 0.88 | DNM1 (0.58) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL26577995 | 0.87 | DNM1 (0.45) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL16921103 | 0.87 | LPAR1 (0.47) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL16921097 | 0.87 | LPAR1 (0.47) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL16921081 | 0.87 | LPAR1 (0.47) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL16921129 | 0.87 | LPAR1 (0.47) | DNM1LPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL16921161 | 0.87 | LPAR1 (0.47) | DNM1LPAR1LPAR3LPAR6LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | DNM1 1792/4885LPAR1 290/4885LPAR3 512/4885 |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | DNM1 1792/4885LPAR1 290/4885LPAR3 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.